Senti Biosciences, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Celadon Partners SPV 24 | — | C | 9,777,000 | — | — | 9,777,000 | Mar 10, 2025 |
| Florence Anthony A. Jr. | — | C | 3,333,000 | — | — | 3,775,615 | Mar 10, 2025 |
| Bayer US Holding LP | — | C | 2,222,000 | — | — | 2,809,848 | Mar 10, 2025 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | C | 33,000 | $2.25 | $74,250 | 33,000 | Mar 10, 2025 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Award / Grant | 78,363 | — | — | 86,984 | Mar 7, 2025 |
| Lu Timothy K | CEO and Interim PFO and PAO | Award / Grant | 642,358 | — | — | 724,440 | Mar 7, 2025 |
| Lu Timothy K | CEO | Sale | 545 | $4.36 | $2,376 | 82,082 | Feb 4, 2025 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Sale | 182 | $4.37 | $795 | 8,621 | Feb 4, 2025 |
| Rajangam Kanya | Chief Medical & Devt. Officer | Award / Grant | 101,000 | — | — | 101,000 | Feb 1, 2024 |
| Lu Timothy K | CEO and President | Award / Grant | 306,000 | — | — | 865,496 | Feb 1, 2024 |
| KNOBELMAN DEBORAH | Chief Financial Officer | Award / Grant | 101,000 | — | — | 131,000 | Feb 1, 2024 |
| KNOBELMAN DEBORAH | Chief Financial Officer | Award / Grant | 30,000 | — | — | 30,000 | Oct 3, 2022 |
| Epstein David R | — | Award / Grant | 112,519 | — | — | 123,252 | Jun 8, 2022 |
| Farokhzad Omid | — | Award / Grant | 250,000 | $10.00 | $2,500,000 | 250,000 | Jun 8, 2022 |
| Dynamics Sponsor LLC | — | Other | 6,465,500 | — | — | — | Jun 8, 2022 |